JP2021512123A5 - - Google Patents
Info
- Publication number
- JP2021512123A5 JP2021512123A5 JP2020541958A JP2020541958A JP2021512123A5 JP 2021512123 A5 JP2021512123 A5 JP 2021512123A5 JP 2020541958 A JP2020541958 A JP 2020541958A JP 2020541958 A JP2020541958 A JP 2020541958A JP 2021512123 A5 JP2021512123 A5 JP 2021512123A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic composition
- composition according
- nucleic acid
- arm region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625623P | 2018-02-02 | 2018-02-02 | |
| US62/625,623 | 2018-02-02 | ||
| PCT/US2019/016413 WO2019152884A1 (en) | 2018-02-02 | 2019-02-01 | Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512123A JP2021512123A (ja) | 2021-05-13 |
| JP2021512123A5 true JP2021512123A5 (https=) | 2022-02-03 |
| JP7409612B2 JP7409612B2 (ja) | 2024-01-09 |
Family
ID=67479930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541958A Active JP7409612B2 (ja) | 2018-02-02 | 2019-02-01 | トリパタイトモチーフ含有蛋白質１６（ｔｒｉｍ１６）シグナル伝達を誘導するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210046168A1 (https=) |
| EP (1) | EP3746088B1 (https=) |
| JP (1) | JP7409612B2 (https=) |
| KR (1) | KR102828978B1 (https=) |
| CN (1) | CN111836623A (https=) |
| AU (1) | AU2019215191B2 (https=) |
| BR (1) | BR112020015821A2 (https=) |
| RU (1) | RU2020128838A (https=) |
| WO (1) | WO2019152884A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| WO2021067480A1 (en) * | 2019-10-02 | 2021-04-08 | University Of Washington | Compositions and methods for treatment of hepatitis b virus infection |
| WO2021097347A1 (en) * | 2019-11-15 | 2021-05-20 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
| KR20220156933A (ko) | 2020-03-23 | 2022-11-28 | 에이치디티 바이오 코포레이션 | Rna의 전달을 위한 조성물 및 방법 |
| EP4112665A4 (en) * | 2020-03-27 | 2024-04-10 | Mitsui Chemicals, Inc. | LIGHT-CURING COMPOSITION, CURED PRODUCT AND DENTAL PRODUCT |
| AU2022302143A1 (en) | 2021-07-02 | 2024-01-18 | Yale University | Compositions and methods for treating cancers |
| EP4395832A1 (en) | 2021-08-31 | 2024-07-10 | Yale University | Compositions and methods for treating cancers |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| WO2023048760A1 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| CA3232719A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Sars-cov-2 rna vaccine compositions and methods of use |
| US20230303719A1 (en) | 2022-03-03 | 2023-09-28 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
| WO2026039779A1 (en) | 2024-08-15 | 2026-02-19 | Yale University | Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078595A2 (en) * | 2002-03-15 | 2003-09-25 | Astral, Inc. | Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
| ES2911034T3 (es) | 2006-08-08 | 2022-05-17 | Univ Bonn Rheinische Friedrich Wilhelms | Estructura y uso de oligonucleótidos 5' fosfato |
| BRPI1100857A2 (pt) * | 2011-03-18 | 2013-05-21 | Eduardo Nowill Alexandre | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
| US9775894B2 (en) | 2013-07-09 | 2017-10-03 | University Of Washington Through Its Center For Commercialization | Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling |
| WO2016179034A2 (en) * | 2015-05-01 | 2016-11-10 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs |
| MA44252A (fr) * | 2016-02-16 | 2018-12-26 | Harvard College | Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation |
-
2019
- 2019-02-01 WO PCT/US2019/016413 patent/WO2019152884A1/en not_active Ceased
- 2019-02-01 CN CN201980018082.3A patent/CN111836623A/zh active Pending
- 2019-02-01 US US16/966,851 patent/US20210046168A1/en active Pending
- 2019-02-01 JP JP2020541958A patent/JP7409612B2/ja active Active
- 2019-02-01 EP EP19748292.0A patent/EP3746088B1/en active Active
- 2019-02-01 KR KR1020207025399A patent/KR102828978B1/ko active Active
- 2019-02-01 AU AU2019215191A patent/AU2019215191B2/en active Active
- 2019-02-01 BR BR112020015821-6A patent/BR112020015821A2/pt unknown
- 2019-02-01 RU RU2020128838A patent/RU2020128838A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512123A5 (https=) | ||
| RU2020128838A (ru) | Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16) | |
| JP2548527B2 (ja) | 腫瘍壊死因子の産生を増加する方法 | |
| RU2009117325A (ru) | Слитый белок теломеразной обратной транскриптазы, кодирующие его нуклеотиды и их применение | |
| JP2023519173A5 (https=) | ||
| JP2019193662A5 (https=) | ||
| JP2008056679A5 (https=) | ||
| JP2014506913A5 (https=) | ||
| TR200700740T2 (tr) | Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler | |
| AR079555A1 (es) | Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) | |
| CN115176009A (zh) | 用于靶向pd-l1的方法和组合物 | |
| US10435672B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| JP2021525549A5 (https=) | ||
| JP2024513559A5 (https=) | ||
| JP2023510121A5 (https=) | ||
| JP2023522630A5 (https=) | ||
| JP2003530088A5 (https=) | ||
| JP2022507373A5 (https=) | ||
| RU2004122084A (ru) | Пептиды для лечения рака, ассоциированного с папилломавирусом (hpv) человека, и других эпителиальных опухолей | |
| JP2021536239A5 (https=) | ||
| CN104292337A (zh) | 猪融合干扰素 | |
| JP2024503703A5 (https=) | ||
| AU2012281131B2 (en) | Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment | |
| CN115804853A (zh) | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 | |
| RU2020100072A (ru) | Иммуногенные композиции, содержащие cea, muc1 и tert |